Healius shares soar amid reports of merger talks with Australian Clinical Labs
Make us a preferred source
Make us a preferred source on Google
The news: Pathology services provider Healius was the top performing company across the ASX 200 index after morning trade, as a media report said it had resumed talks with smaller rival Australian Clinical Labs (ACL) over a possible merger.
The numbers: Healius shares were up 6.3% to $1.48 by midday AEDT. ACL shares rose 0.6% to $3.68.
The context: The rally followed a report in The Australian, citing unnamed sources, that said the two pathology services providers have resumed talks about a potential $2 billion deal.
Healius rejected a hostile takeover bid from ACL in 2023, describing the move as opportunistic.
The source: The Australian
